Status:
TERMINATED
Controlling Rapid Atrial Fibrillation With Dexmedetomidine
Lead Sponsor:
Stony Brook University
Conditions:
Rapid Atrial Fibrillation
Heart Rate Control
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized, double blinded study...
Detailed Description
Dexmedetomidine is a commonly used sedative/anxiolytic agent in the ICU with sympatholytic properties that can cause a decrease in heart rate. Eligible patients will be randomized into one of two grou...
Eligibility Criteria
Inclusion
- Adult patients in a SBU Hospital ICU with rapid-AF (with ventricular rates \>100 bpm).
- Patient screening will be conducted prior to patient or LAR consent.
Exclusion
- Patients age \<18yrs;
- Anticipated ICU stay \<11hrs;
- Permanently paced heart rhythm;
- Known 2nd or 3rd degree heart block;
- Junctional rhythms;
- Known pregnancy;
- Known allergy to Dexmedetomidine;
- Receiving Dexmedetomidine prior to study onset;
- Non-intubated patients w/ Glasgow Coma Scale \<8;
- Weight \>400lbs (protocol dosing restriction);
- Untreated, symptomatic hypotension (SBP\<90mmHg);
- Received amiodarone, lidocaine, or mexiletine w/in 4hrs prior to consent.
Key Trial Info
Start Date :
August 21 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT04042727
Start Date
August 21 2019
End Date
December 31 2021
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stony Brook University Hospital
Stony Brook, New York, United States, 11794